Inhalon Biopharma, Inc.

Inhalon Biopharma, Inc. is a clinical-stage biopharmaceutical company located in Morrisville, North Carolina, focused on developing innovative inhaled monoclonal antibody therapies for respiratory infections. The company specializes in creating advanced therapeutic interventions targeting various respiratory viruses through a unique platform of inhaled, muco-trapping antibody treatments that can be administered directly to the respiratory tract using handheld nebulizers. As a for-profit corporate entity registered in SAM.gov, Inhalon provides specialized research and development services to federal agencies, particularly in the domain of respiratory disease therapeutics.

Regarding federal contract awards, Inhalon has secured a significant contract from the Defense Health Agency valued at $2,234,650 for developing IN-007, an inhaled treatment utilizing human ACE2 to target and neutralize various pathogens. The contract, awarded on September 23, 2024, focuses on developing a broadly deployable inhaled treatment against pathogens and will be performed at the company's Morrisville facilities. The contract is a fixed-price level of effort contract with no specific set-aside designation and is scheduled for completion by December 22, 2026. The work involves comprehensive research activities including cell line development, GMP manufacturing, animal studies, and regulatory submissions.

In terms of federal grant awards, Inhalon has received multiple project grants from the National Institute of Allergy and Infectious Diseases (NIAID) totaling approximately $3 million. These grants support the development of various inhaled monoclonal antibody therapies targeting specific respiratory infections, including treatments for human metapneumovirus (MPV), respiratory syncytial virus (RSV), influenza A, and COVID-19. The grants, ranging from $1,013,003 to $1,013,468, are structured as Project Grants under the Allergy and Infectious Diseases Research program and focus on critical research activities such as producing GLP-compliant antibody batches, conducting IND-enabling toxicology and efficacy studies, and preparing for clinical trials. Each grant supports Inhalon's innovative approach of developing inhaled, muco-trapping antibody therapies that can be self-administered at home and target respiratory infections directly in the airways.